Townsend Adam J.

CIK 00017735881 companyWALTHAM, MA

SEC Profile

Transactions

Companies

Filings

CIK

0001773588

Recent Transactions

50 trades

Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2025-01-29$29.52/sh−695→ 84,050 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2025-01-22$30.43/sh−3,323→ 84,745 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2025-01-17$29.96/sh−2,201→ 88,068 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2025-01-13$28.70/sh−2,685→ 90,269 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-02-12$67.77/sh−1,148→ 92,453 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-01-29$64.14/sh−906→ 93,601 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-01-22$65.00/sh−3,413→ 94,507 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-01-16$66.81/sh−2,235→ 97,920 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2024-01-16+23,748→ 100,155 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2024-01-16$66.30/sh+34,533→ 34,533 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-12-01$61.31/sh−42,443→ 76,407 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-12-01$15.09/sh+110,000→ 186,407 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2023-12-01−110,000→ 172,500 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-12-01$60.50/sh−67,557→ 118,850 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-05-03$15.09/sh+5,000→ 80,995 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2023-05-03−5,000→ 282,500 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-05-03$82.71/sh−5,000→ 75,995 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-04-03$74.05/sh−5,000→ 75,995 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2023-04-03−5,000→ 287,500 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-04-03$15.09/sh+5,000→ 80,995 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-03-03$15.09/sh+5,000→ 80,995 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-03-03$63.84/sh−5,000→ 75,995 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2023-03-03−5,000→ 292,500 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-02-21+9,886→ 77,036 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2023-02-21+14,023→ 14,023 total
Tax Payment
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-02-21$58.50/sh−1,041→ 75,995 total
Tax Payment
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-02-10$51.21/sh−782→ 67,150 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2023-02-03−5,000→ 297,500 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-02-03$15.09/sh+5,000→ 72,932 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-02-03$55.85/sh−5,000→ 67,932 total
Tax Payment
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-01-27$52.77/sh−551→ 67,932 total
Tax Payment
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-01-20$52.05/sh−1,912→ 68,483 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-01-12+27,488→ 70,395 total
Award
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2023-01-12$52.66/sh+43,183→ 43,183 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-01-03$50.70/sh−5,000→ 42,907 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2023-01-03$15.09/sh+5,000→ 47,907 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2023-01-03−5,000→ 302,500 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2022-12-05$15.09/sh−5,000→ 47,907 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2022-12-05$50.38/sh−5,000→ 42,907 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2022-12-05−5,000→ 307,500 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2022-11-03$58.54/sh−5,000→ 42,907 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2022-11-03−5,000→ 312,500 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2022-11-03$15.09/sh−5,000→ 47,907 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2022-10-03$15.09/sh+5,000→ 47,907 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2022-10-03$66.69/sh−5,000→ 42,907 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2022-10-03−5,000→ 317,500 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2022-09-06−5,000→ 322,500 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2022-09-06$15.09/sh+5,000→ 47,907 total
Sale
Apellis Pharmaceuticals, Inc.$APLS
Common Stock
2022-09-06$60.38/sh−5,000→ 42,907 total
Exercise/Conversion
Apellis Pharmaceuticals, Inc.$APLS
Stock Option (Right to Buy)
2022-08-15−12,500→ 327,500 total

Companies

Apellis Pharmaceuticals, Inc.
Chief Commercial Officer
$APLS

Recent Filings

Address

C/O APELLIS PHARMACEUTICALS, INC. 100 FIFTH AVENUE, 3RD FLOOR

WALTHAM, MA, 02451

View on SEC.gov